CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'

Max Bayer

Pharma Reporter

CBER Director Vinay Prasad says the benefits of Covid-19 vaccination have depreciated and may no longer outweigh the risks in adults who aren’t prone to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Pfizer ends Phase 2 trial for final Trillium CD47 drug

Apple Tree Partners' biotechs 'face imminent collapse' as firm battles Russian investor in court

Supreme Court passes on Oklahoma’s drug middlemen spat

AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal

Sage plans to lay off almost every employee after inking Supernus deal

Amgen’s stomach cancer drug boosts survival in Phase 3, but ocular side effects leave questions

CBER chief Prasad sug­gests Covid vac­cine harms may out­weigh ben­e­fits in 'low-risk pop­u­la­tion­s'

Max Bayer

Pharma Reporter

Sign up to read this article for free.

more like this

Pfiz­er ends Phase 2 tri­al for fi­nal Tril­li­um CD47 drug

Ap­ple Tree Part­ner­s' biotechs 'face im­mi­nent col­lapse' as firm bat­tles Russ­ian in­vestor in court

Supreme Court pass­es on Ok­la­homa’s drug mid­dle­men spat

Ab­b­Vie bags Cap­stan’s in vi­vo CAR-T work with $2.1B buy­out deal

Sage plans to lay off al­most every em­ploy­ee af­ter ink­ing Su­per­nus deal

Am­gen’s stom­ach can­cer drug boosts sur­vival in Phase 3, but oc­u­lar side ef­fects leave ques­tions

CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'

Pfizer ends Phase 2 trial for final Trillium CD47 drug

Apple Tree Partners' biotechs 'face imminent collapse' as firm battles Russian investor in court

Supreme Court passes on Oklahoma’s drug middlemen spat

AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal

Sage plans to lay off almost every employee after inking Supernus deal

Amgen’s stomach cancer drug boosts survival in Phase 3, but ocular side effects leave questions